Rapport Therapeutics Prices $200 Million Share Sale At $21, Below Tuesday's $27.54 Price

The biotech also priced $150 million of 2.25% convertible notes and a private placement, and says the money funds operations through the end of 2029.

Share
Rapport Therapeutics Prices $200 Million Share Sale At $21, Below Tuesday's $27.54 Price

Rapport Therapeutics, a clinical-stage biotech developing medicines for neurological and psychiatric disorders, priced a $200.0 million stock offering at $21.00 a share on Wednesday, a 23.7% discount to the $27.54 last reported sale price on October 27. It paired the sale with $150 million of convertible notes and a private placement.

Three deals priced at once

The public offering covers 8,333,334 common shares, plus pre-funded warrants (shares with a nominal $0.001 exercise price) for up to 1,190,476 shares. Underwriters hold an option to buy additional shares, which would lift the total to 9,761,905 shares and the offering to about $230.0 million. The underwriting discount is $1.26 a share, about $12.0 million in all.

A single investor agreed to buy 1,428,571 shares at $21.00 in a concurrent private placement. Rapport estimates net proceeds from the share offering and the private placement at about $215.7 million, or about $243.9 million if the underwriters' option is exercised in full.

The stock offering and notes are set to settle on October 30.

Notes convert at $26.7750

The $150,000,000 of 2.25% convertible senior notes due December 1, 2032 are senior unsecured. The initial conversion price is about $26.7750 a share, roughly 27.50% above the $21.00 offering price. Underwriters can buy up to an additional $22,500,000 of notes, and net proceeds are estimated at about $145.0 million.

Rapport agreed to settle conversions in physical shares and to cap any holder's conversion at a beneficial ownership limit of 19.99% of shares outstanding. It can redeem the notes for cash on or after the later of December 6, 2030 and 60 days after reported topline data from its planned RAP-219 trials, if the stock has traded at least 130% of the conversion price for 20 of 30 trading days.

Money for RAP-219 trials

Rapport has no products on the market. Its lead candidate, RAP-219, is being studied in focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. The company said it will use proceeds "primarily to fund our ongoing and planned clinical trials advancing RAP-219, for other research and development, and for working capital and general corporate purposes."

Rapport said the proceeds, with its existing cash and short-term investments, should fund operations through the end of 2029, an estimate it cautions rests on assumptions that may prove wrong. Morgan Stanley, Leerink Partners and Evercore lead the book-running group, with BTIG and Citizens JMP also joint managers on the stock sale.

Rapport's market value stood at $1.3 billion at the $27.54 price before the pricing.

Sources

More on Rapport Therapeutics

All Rapport Therapeutics (RAPP) coverage →